Gene
PTPRD
protein tyrosine phosphatase receptor type D
Explore in graph →CI-GENE-00022530HGNC:9668 ENSG00000153707 NCBI 5789 CIViC Cancer geneApproved
Curated evidence
Clinical evidence (4)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26267899
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PTPRD Mutation1 | ||||||||
| JSI-124 | Head and Neck Carcinoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID807In this preclinical study, loss-of-function of PTPRD was mainly caused by mutation in head and neck cancer, as identified in TCGA data. PTPRD mutated cell-lines were more sensitive to STAT3 inhibition… (full text at CIViC) PMID 26267899 · Peyser et al., 2015 · Open in CIViC | civic |
| PTPRD R995C1 | ||||||||
| IGF1R Monoclonal Antibody + TemsirolimusCombination | Ewing Sarcoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID10061An analysis of 8 ewing sarcoma patients revealed PTPRD mutations in 3 cases (V253I/W775*, T781A, R995C). 2 of 3 cases showed complete response (RECIST criteria) to IGF1R mAb based therapies. The R995C… | |
Cohorts
Alteration frequency by cohort (200)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
- Source
- cBioPortal for Cancer Genomics (public studies)
- Dataset
- cBioPortal mutated genes by study
- Version
- cbioportal-2026-09-01
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- cohort
- License
- ODC Open Database License (ODC-ODbL) unless otherwise noted per study; attribution to the original studies required
- Run
- ING-CBIOPORTAL-20260908-000001
| Cohort | Mapped cancer | Alteration | Affected (n) | Profiled (n) | Frequency (%) | Rank in cohort | Source |
|---|---|---|---|---|---|---|---|
| Prostate Cancer-IDH Driver Mutant Cohort (MSK, 2024) prad_idhmut_msk_2025 | Prostate Adenocarcinoma | Ssm | 3 | 99 | 3% |
Literature
Linked publications (2)
25 per page, newest first.
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)